Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.40
Bid: 4.12
Ask: 4.70
Change: 0.94 (27.09%)
Spread: 0.58 (14.078%)
Open: 3.64
High: 4.80
Low: 3.64
Prev. Close: 3.47
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wilbur Ellis Agreement

14 Jun 2023 07:00

RNS Number : 6732C
Plant Health Care PLC
14 June 2023
 

14 June 2023

 

Plant Health Care plc

 ("Plant Health Care" or the "Company")

 

Plant Health Care® ("PHC") and Wilbur-Ellis® Agribusiness Announce Distribution Agreement to Support First OBRONATM Commercial Sales in the U.S.

 

Plant Health Care® (AIM.PHC.L), a leading provider of peptides for plant protection to global agriculture markets, is pleased to announce it has concluded a distribution agreement ("The Agreement") with Wilbur-Ellis® Agribusiness, one of the largest U.S. retailers of agricultural products. The Agreement will support commercial sales of OBRONATM, a foliar fungicide recently approved by US EPA which is expected to be available within key US markets during the summer of 2023. Obrona is a unique product developed to help growers control a wide range of fungal and bacterial plant pathogens within fruits, nuts, vegetables, and row crops.

 

Plant Health Care and Wilbur-Ellis have been working together in an exclusive partnership since 2020 to evaluate and develop PHC279, the active ingredient in OBRONA, for high value specialty and row crop markets. Multiple years of field trials have validated product efficacy to support initial launch focused on corn diseases, such as tar spot (Phyllachora maydis), Gray leaf spot (Cercospora zeae-maydis), and common rust (Puccinia sorghi), as well as powdery and downy mildew and various other diseases in grapes, as well as white mold (Sclerotinia sclerotiorum) and other diseases affecting leafy vegetables within key Western US states.

 

Derived from naturally occurring proteins, PHC279 is the first product from the Company's PREtec technology platform (Vaccines for Plants™) that will be available to US farmers. PREtec stimulates crop growth and enhances crop resistance to fungal and bacterial diseases and improves crop quality and yield. The Company's initial PREtec product, Saori® is successfully being used in Brazil as a seed treatment to control an array of soybean diseases including Asian Soybean Rust (Phakopsora spp.).

 

PREtec provides growers with a novel and environmentally friendly approach to growing crops and is compatible with mainstream agricultural practices. As part of an integrated pest management program, OBRONA will reduce reliance on older synthetic pesticides and will provide growers with a valuable tool to proactively manage disease resistance. The availability of OBRONA will support farmers seeking to use more sustainable and environmentally friendly practices while continuing to provide safe, abundant, and high-quality food.

 

Plant Health Care continues to expand into new markets around the world through strategic partnerships with major global distribution partners. The Company is on track to achieve revenue of $30 million by 2025, through the launch of new products and continued growth through current and future distributor relationships, and to achieve cash breakeven and profit along that track.

 

Jeff Tweedy, CEO of Plant Health Care, said: ‟Having worked with Wilbur-Ellis on the development of OBRONA for more than three years, I am gratified that this new agreement will bring OBRONA to the market to enable control of many of the most recalcitrant fungal and bacterial pathogens challenging growers today. OBRONA will support sustainable agriculture with better crops delivering higher yield for thousands of U.S. farmers."

 

 

Scott Addy, Wilbur-Ellis Agribusiness VP Branded Technologies and Biological Solutions, said: "We are pleased that our partnership with Plant Health Care has resulted in the approval of OBRONA and are looking forward to launching the product this summer to deliver value to the grower in a sustainable way. We expect that there will be many other products that follow, and we will continue to offer our growers biological options to solve their pest issues."

 

 

# # #

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

About the Wilbur-Ellis Companies 

 

Founded in 1921, the Wilbur-Ellis companies are leading marketers, distributors and manufacturers of agricultural products and animal nutrients. By developing strong relationships, making strategic market investments, and capitalizing on new opportunities, the Wilbur-Ellis companies have continued to grow the business with sales of over $3.5 billion. For more information, please visit www.wilburellis.com

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

Tel: +1 919 926 1600

Cenkos Securities plc - Nomad & Broker Neil McDonald / Pete Lynch

Tel: +44 (0) 131 220 9771

SEC Newgate (Financial Communications) Robin Tozer / George Esmond / Harry Handyside

Tel: +44 (0)7540 106 366 Email: phc@secnewgate.co.uk

For further information about Wilbur-Ellis, please contact:

Jeanne Forbis, email:jforbis@wilburellis.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEASKLFDLDEEA
Date   Source Headline
11th Nov 20144:05 pmRNSHolding(s) in Company
30th Oct 20147:00 amRNSPHC & Sipcam Enter Agreement
27th Oct 20147:00 amRNS3G Peptide Technology Platform shows major promise
23rd Oct 20144:29 pmRNSHolding(s) in Company
6th Oct 201411:25 amRNSDirector/PDMR Shareholding
2nd Oct 20147:00 amRNSDirector/PDMR Shareholding
15th Sep 20147:00 amRNSHalf Yearly Report
19th Aug 201410:28 amRNSAIM Blocklisting Return
12th Aug 20143:10 pmRNSTR-1 Notification of Major Interest in Shares
22nd Jul 20144:10 pmRNSTR-1 Notification of Major Interest in Shares
30th Jun 20149:18 amRNSTotal Voting Rights
5th Jun 201412:45 pmRNSTR-1 Notification of Major Interest in Shares
22nd May 20147:00 amRNSDelisting of shares from the CISX
8th May 20141:30 pmRNSAGM Voting Results
15th Apr 201411:30 amRNSDirector/PDMR Shareholding
15th Apr 20147:00 amRNSDirector/PDMR Shareholding
9th Apr 20142:15 pmRNSDirector's Dealing - Grant of Share Options
9th Apr 20142:00 pmRNSTR-1 Notification of Major Interest in Shares
7th Apr 20145:15 pmRNSPublication of Annual Report 2013 & Notice of AGM
31st Mar 20143:45 pmRNSTotal Voting Rights
24th Mar 20147:00 amRNSPreliminary Results
3rd Mar 20144:35 pmRNSPrice Monitoring Extension
28th Feb 20141:00 pmRNSTotal Voting Rights
19th Feb 201412:15 pmRNSBlocklisting Interim Review
17th Feb 20149:45 amRNSTR-1 Notification of Major Interest in Shares
6th Feb 20144:40 pmRNSSecond Price Monitoring Extn
6th Feb 20144:35 pmRNSPrice Monitoring Extension
31st Jan 20143:00 pmRNSTotal Voting Rights
15th Jan 20147:00 amRNSTrading Statement
29th Nov 201312:12 pmRNSDirector's Shareholding
25th Nov 20133:15 pmRNSDivestment of non-core subsidiary
18th Oct 20135:00 pmRNSTR-1 Notification of Major Interest in Shares
30th Sep 20135:00 pmRNSTotal Voting Rights
23rd Sep 201310:30 amRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSAppointment of Adviser
18th Sep 20133:15 pmRNSDirector/PDMR Shareholding
16th Sep 20137:03 amRNSDirectorate Change
16th Sep 20137:00 amRNSHalf Yearly Report
19th Aug 20132:30 pmRNSBlocklisting Interim Review
30th Jul 20137:01 amRNSUpdate on Harpin
30th Jul 20137:00 amRNSPHC announces plans for Harpin seed treatment
22nd Jul 201311:00 amRNSPHC hires Glen Donald as VP Business Development
19th Jul 20137:00 amRNSHead Office Relocation,Research Facility Expansion
15th Jul 20135:15 pmRNSDirector/PDMR Shareholding
5th Jul 20137:00 amRNSUpdate on CISX Listing
3rd Jul 20137:00 amRNSNew Long-Term Incentive Plan and Grant of Awards
7th Jun 20134:15 pmRNSDirectorate Change
31st May 201311:30 amRNSTotal Voting Rights
21st May 201312:00 pmRNSHarpin Granted Federal Registration in Mexico
10th May 20134:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.